If you're arguing RDGL can fetch same buyout price post 2022 when last of original patents expired vs, had they gotten to market in 2012 with ten years of strong IP protection left, you can believe whatever you wish. That doesn't make it so. The fact is anybody can make an offset to Radiogel now. Why do we only know of one competitor also pursuing Y90 injectable gel? Cuz there ain't no big bucks in the generic marketplace. Even if Radiogel is first to market and reaches reasonable volume in a few years, it will likely be a low margin product priced to discourage competitive entry. That greatly reduces any potential buyout price. Just common business sense.
And if RDGL isn't first to market, it's survival is reasonably questionable. Likewise for any small company competitor like Betaglue.
Further never said manufacturing in India is a weakness, although I do question if profit can be made there. My point is moronic MK only just figured out he needs operations in India to conduct a valid human trials with a product equivalent to what he intends to peddle to FDA. And yes, FDA rejects studies out of India all the time. That's just a fact.
As far as MK's "playbook working" he's still peddling hopeless IsoPet and since taking over in 2016, he waited until Sept 2021 to approach FDA about Radiogel. Since then he hasn't delivered anything FDA needs to consider Radiogel for USA hunan trials. The guy is a proven incompetent moron.
Market Data 
Markets 
